Triazolines - XXVII. Δ2-1,2,3-triazoline anticonvulsants: Novel 'built-in' heterocyclic prodrugs with a unique 'dual-action' mechanism for impairing excitatory amino acid l-glutamate neurotransmission

Bioorganic and Medicinal Chemistry

Volumn 4, Issue 2, 1996, Pages 165-178

  Kadaba, Pankaja K ^a,b   Stevenson, Paul J ^c   P Nnane, Ivo ^d   Damani, L A ^d  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b K and K Biosciences Inc   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

STAPHYLOCOCCUS PHAGE 3A; ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

1 (4 CHLOROPHENYL) 4,5 DIHYDRO 5 (4 PYRIDYL) 1H 1,2,3 TRIAZOLE; 4,5 DIHYDRO 1H 1,2,3 TRIAZOLE DERIVATIVE; ANTICONVULSIVE AGENT; CHLORIDE CHANNEL; DIZOCILPINE; DRUG METABOLITE; ETHOSUXIMIDE; GLUTAMIC ACID; PHENOBARBITAL; PHENYTOIN; PRODRUG; TRIAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; DIZOCILPINE MALEATE; GLUTAMATE RECEPTOR; ION CHANNEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRIAZOLE DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; GUINEA PIG; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY; ANIMAL; BINDING COMPETITION; DRUG DESIGN; DRUG EFFECT; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION; SYNTHESIS; URINE;

ANIMALS; ANTICONVULSANTS; BINDING, COMPETITIVE; BRAIN; DIZOCILPINE MALEATE; DRUG DESIGN; GLUTAMIC ACID; ION CHANNELS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PRODRUGS; RADIOLIGAND ASSAY; RATS; RECEPTORS, GABA; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC TRANSMISSION; TRIAZOLES;

EID: 0029665798     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/0968-0896(95)00168-9     Document Type: Article

References (34)

1. This paper was presented in parts at the 196th and 200th National Meeting of the American Chemical Society, Abstrs. 1988, MEDI 52, and 1990, MEDI 31, and at the Fourth Chemical Congress of North America, Abstrs. 1991, MEDI 144.
2. Kadaba, P. K. J. Pharm. Sci. 1984, 73, 850.
3. Kadaba, P. K. U.S. Patent 4 511 572, 1985.
4. Kadaba, P. K. U.S. Patent 4 618 681, 1986.
5. Kadaba, P. K. U.S. Patent 4 689 334, 1987.
6. Kadaba, P. K. J. Med. Chem 1988, 31, 196.
7. Kadaba, P. K. U.S. Patent 4 820 721, 1989.
8. Kadaba, P. K.; Slevin, J. T. Epilepsia 1988, 29, 330.
9. Kadaba, P. K.; Slevin, J. T. Pharmaceut. Res. 1989, 6, S-42.
10. Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scoville, B.; White, B. G. Cleve. Clin. Q. 1984, 51, 293.
11. Scheiner, P. In Selective Organic Transformations; Thyagarajan, B. S., Ed.; Wiley-Interscience: New York, 1970; Vol. 1, pp 328-362.
12. Kadaba, P. K.; Stanovnik, B.; Tisler, M. Adv. Heterocycl. Chem. 1984, 37, 217.
13. Kadaba, P. K.; Edelstein, S. B. J. Org. Chem. 1990, 55, 5891.
14. Dermer, O. C.; Ham, G. E. In Ethylenimine and Other Aziridines: Academic: New York, 1969.
15. Testa, B.; Jenner, P. Drug Metabolism: Chemical and Biochemical Aspects; Marcel Dekker: New York, 1976.
16. Stevenson, P. J.; Hauksdottir, R.; Kadaba, P. K.; Damani, L. A. J. Chromatogr. Biomed. Appl. 1990, 533, 248.
17. Hamelijnck, M. A. F.; Stevenson, P. J.; Kadaba, P. K.; Damani, L. A. J. Pharm. Sci. 1992, 81, 392.
18. Stevenson, P. J.; Hamelijnck, M. A. F.; Kadaba, P. K.; Damani, L. A. J. Chromatogr. Biomed. Appl. 1991, 563, 419.
19. Tita, T.; Kadaba, P. K.; Crooks, P. A. J. Biopharm. Sci. 1990, 1, 171.
20. Neurotransmitters and Epilepsy; Fisher, R. S.; Coyle, J. T., Eds.; Wiley-Liss: New York, 1991.
21. GABA Mechanisms in Epilepsy; Tunnicliff, G.; Raess, B. U., Eds.; Wiley-Liss: New York, 1991.
22. Kogure, K. In Neurotransmitters, Focus on Excitatory Amino Acids; Kanazawa, I., Ed.; Excerpta Medica: Japan, 1988.
23. Tita, T.; Slevin, J. T.; Kadaba, P. K.; Deshmukh, T. R. Pharmaceut. Res. 1991, S-269.
24. Nicholls, D.; Attwell, D. Trends Pharmacol. Sci. 1990, 11, 462.
25. Choi, D. W. Cerebrovas. Brain Metab. Revs. 1990, 2, 105.
26. Potashner, S. J. J. Neurochem. 1979, 32, 103.
27. McNamara, J. O.; Russell, R. D.; Rigsbee, L.; Bonhaus, D. W. Neuropharmacol. 1988, 27, 563.
28. Kadaba, P. K. Tetrahedron 1966, 22, 2453.
29. Kadaba, P. K. J. Heterocycl. Chem. 1975, 12, 143.
30. Kadaba, P. K.; Parmley, G.; Crooks, P. A.; Agha, B. J. Heterocycl. Chem. 1993, 30, 1191.
31. Dahlman, D. L.; Kadaba, P. K. Pestic. Sci. 1988, 22, 71.
32. Lawrence, L. J.; Palmer, C. J.; Gee, K. W.; Wang, X.; Yamamura, H. I.; Casida, J. E. J. Neurochem. 1985, 45, 798.
33. Javitt, D. C.; Zukin, S. R. Mol. Pharmacol. 1989, 35, 387.
34. Graham, Jr. L. T.; Aprison, M. H. Analyt. Biochem. 1966, 15, 487.